ReviewJournal of gastroenterology2021
The gut mycobiome: a novel player in chronic liver diseases.
Review in Journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- The mycobiome, virome and archaeome in gastrointestinal cancers: molecular pathogenesis and therapeutic intervention.Molecular cancer · 2026Review
- Intestinal fungi shape the biology of the mammalian gut.PLoS pathogens · 2026Article
- The role and possible mechanism of intestinal fungi in the progression of chronic liver diseases.NPJ biofilms and microbiomes · 2026Review
- Article
- Gut Microbial Metabolism in Colorectal Cancer.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatures for early mortality in acute liver failure.Clinical and molecular hepatology · 2025Article
- The Human Mycobiome: Composition, Immune Interactions, and Impact on Disease.International journal of molecular sciences · 2025Review
- Invasive fungal infections in patients with liver disease: immunological and clinical considerations for the intensive care unit.Intensive care medicine · 2025Review
- The mycobiome in human cancer: analytical challenges, molecular mechanisms, and therapeutic implications.Molecular cancer · 2025Review
- Tumor-related fungi and crosstalk with gut fungi in the tumor microenvironment.Cancer biology & medicine · 2024Review
- Gut mycobiome alterations and implications for liver diseases.PLoS pathogens · 2024Review
- The Protective Effect ofMolecules (Basel, Switzerland) · 2023Article
- Development of gut mycobiome in infants and young children: a prospective cohort study.Pediatric research · 2023Article
- Alcohol-associated bowel disease: new insights into pathogenesis.eGastroenterology · 2023Article
- Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease.Cell host & microbe · 2023Article
- Compositional Differences of Meconium Microbiomes of Preterm and Term Infants, and Infants That Developed Necrotizing Enterocolitis or Feeding Intolerance.Pathogens (Basel, Switzerland) · 2022Article
- Expansion of Opportunistic Enteric Fungal Pathogens and Occurrence of Gut Inflammation in Human Liver Echinococcosis.Microbiology spectrum · 2022Article
- Could gut mycobiome play a role in NAFLD pathogenesis? Insights and therapeutic perspectives.Metabolism open · 2022Article
- Trust Your Gut: The Association of Gut Microbiota and Liver Disease.Microorganisms · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 4 countries.
Funding
Abstract
The human gut microbiome (bacteria, fungi, viruses, and archaea) is a complex and diverse ecosystem. It plays an important role in human health, but is involved in several intestinal and extraintestinal diseases. Most research to date has focused on the role of bacteria, while studies focusing on fungi (also referred to as "mycobiome" or "fungome") are still in its infancy. In this review, we focus on the existing literature available about the gut mycobiome with an emphasis on compositional mycobiome changes associated with liver diseases, the impact on pathogenesis of disease, and its potential use as therapeutic targets. We also provide insights into current methodologies of studying mycobiome, and we highlight the interkingdom interactions in the context of disease and how they affect health of the host. Herein, by focusing on the gut mycobiome, this review provides novel insights and directions for liver research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.